TNSN96100A1 - MELANGE D'ACIDES α - AMINES ET D'ACIDES BETA - AMINES, ET PROCEDE POUR AMELIORER LA TOLERANCE D'ACIDES BETA - AMINES ACTIFS D'UN POINT DE VUE PHARMACEUTIQUE - Google Patents

MELANGE D'ACIDES α - AMINES ET D'ACIDES BETA - AMINES, ET PROCEDE POUR AMELIORER LA TOLERANCE D'ACIDES BETA - AMINES ACTIFS D'UN POINT DE VUE PHARMACEUTIQUE

Info

Publication number
TNSN96100A1
TNSN96100A1 TNTNSN96100A TNSN96100A TNSN96100A1 TN SN96100 A1 TNSN96100 A1 TN SN96100A1 TN TNSN96100 A TNTNSN96100 A TN TNSN96100A TN SN96100 A TNSN96100 A TN SN96100A TN SN96100 A1 TNSN96100 A1 TN SN96100A1
Authority
TN
Tunisia
Prior art keywords
beta
amino acids
acids
tolerance
improving
Prior art date
Application number
TNTNSN96100A
Other languages
English (en)
Inventor
Michael Matzke Dr
Hans-Christian Milizer Dr
Joachim Mittendorf Dr
Franz Kunisch Dr
Axel Schmidt Dr
Wolfgang Schonfeld Dr
Karl Ziegelbauer Dr
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of TNSN96100A1 publication Critical patent/TNSN96100A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyrrole Compounds (AREA)

Abstract

LA PRESENTE INVENTION CONCERNE DES MELANGES D'ACIDES α -AMINES ET/OU DE LEURS DERIVES ET D'ACIDES CYCLOPENTANE- BETA -AMINES ET/OU DE LEURS DERIVES, DES PEPTIDES DES ACIDES α - AMINES ET DES ACIDES CYCLOPENTANE BETA - AMINES MENTIONNES CI-DESSUS, ET DES MELANGES CI-DESSUS ET DES PEPTIDES, QUI PRESENTENT UNE MEILLEURE TOLERANCE CHEZ LES ANIMAUX A SANG CHAUD, PAR COMPARAISON AVEC LES ACIDES CYCLOPENTANE BETA -AMINES PURS.
TNTNSN96100A 1995-07-19 1996-07-18 MELANGE D'ACIDES α - AMINES ET D'ACIDES BETA - AMINES, ET PROCEDE POUR AMELIORER LA TOLERANCE D'ACIDES BETA - AMINES ACTIFS D'UN POINT DE VUE PHARMACEUTIQUE TNSN96100A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19526274A DE19526274A1 (de) 1995-07-19 1995-07-19 Verbesserung der Verträglichkeit von pharmazeutisch wirksamen beta-Aminosäuren

Publications (1)

Publication Number Publication Date
TNSN96100A1 true TNSN96100A1 (fr) 2005-03-15

Family

ID=7767189

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN96100A TNSN96100A1 (fr) 1995-07-19 1996-07-18 MELANGE D'ACIDES α - AMINES ET D'ACIDES BETA - AMINES, ET PROCEDE POUR AMELIORER LA TOLERANCE D'ACIDES BETA - AMINES ACTIFS D'UN POINT DE VUE PHARMACEUTIQUE

Country Status (44)

Country Link
US (1) US5935988A (fr)
EP (2) EP1043332B1 (fr)
JP (2) JP3891503B2 (fr)
KR (1) KR100433968B1 (fr)
CN (1) CN1115145C (fr)
AR (1) AR003465A1 (fr)
AT (2) ATE344274T1 (fr)
AU (1) AU713555B2 (fr)
BG (1) BG62134B1 (fr)
BR (1) BR9603124A (fr)
CA (1) CA2181308A1 (fr)
CO (1) CO4700525A1 (fr)
CU (1) CU22820A3 (fr)
CZ (2) CZ287896B6 (fr)
DE (3) DE19526274A1 (fr)
DK (2) DK1043332T3 (fr)
DZ (1) DZ2073A1 (fr)
EE (1) EE03803B1 (fr)
ES (2) ES2154761T3 (fr)
GR (1) GR3035601T3 (fr)
HR (1) HRP960303B1 (fr)
HU (1) HUP9601977A3 (fr)
IL (1) IL118869A (fr)
MA (1) MA23940A1 (fr)
MX (1) MX9602836A (fr)
NO (1) NO315926B1 (fr)
NZ (1) NZ299008A (fr)
PE (1) PE9398A1 (fr)
PL (1) PL184861B1 (fr)
PT (2) PT754678E (fr)
RO (1) RO118656B1 (fr)
RS (1) RS49520B (fr)
RU (1) RU2181123C2 (fr)
SA (1) SA96170491B1 (fr)
SG (1) SG47158A1 (fr)
SI (2) SI0754678T1 (fr)
SK (2) SK284733B6 (fr)
SV (1) SV1996000062A (fr)
TN (1) TNSN96100A1 (fr)
TR (1) TR199600583A2 (fr)
TW (1) TW496737B (fr)
UA (1) UA46725C2 (fr)
YU (1) YU20050685A (fr)
ZA (1) ZA966111B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191306B1 (en) * 1999-08-03 2001-02-20 Eastman Chemical Company Process for the preparation of cyclopropylglycine
KR20010073441A (ko) * 2000-01-14 2001-08-01 최인도 패류종묘 착상판의 제조방법
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7659253B2 (en) * 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
KR101159477B1 (ko) * 2003-05-29 2012-07-02 샤이어 엘엘씨 남용 방지성 암페타민 화합물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8716278D0 (en) * 1987-07-10 1987-08-19 Fujisawa Pharmaceutical Co Antimicrobial agent
JPH02174753A (ja) * 1988-08-25 1990-07-06 Fujisawa Pharmaceut Co Ltd シス―２―アミノシクロペンタンカルボン酸誘導体およびその製法ならびに抗菌剤
RU2030422C1 (ru) * 1990-04-27 1995-03-10 Фармацевтическое акционерное общество "Феррейн" Способ получения карнозина
AU673824B2 (en) * 1992-05-29 1996-11-28 Bayer Aktiengesellschaft Cyclopentane- and -pentene-beta-amino acids
US5631291A (en) * 1992-05-29 1997-05-20 Bayer Aktiengesellschaft Cyclopentane- and -pentene-β-amino acids
DE4302155A1 (de) * 1993-01-27 1994-07-28 Bayer Ag Verwendung von Cyclopentan- und -penten-beta-Aminosäuren
GB9216441D0 (en) * 1992-08-03 1992-09-16 Ici Plc Fungicidal process
WO1995007022A1 (fr) * 1993-09-07 1995-03-16 Zeneca Limited Fongicides
DE19548825C2 (de) * 1995-12-27 1999-03-25 Rolf Dr Hermann Neue, substituierte Cyclopentylaminderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19604225A1 (de) * 1996-02-06 1997-08-07 Bayer Ag Stoffzusammensetzungen aus alpha-Aminosäuren und Cyclohexen-beta-aminosäuren

Also Published As

Publication number Publication date
HRP960303A2 (en) 1998-02-28
BG100716A (bg) 1997-04-30
PT1043332E (pt) 2007-01-31
RS49520B (sr) 2006-10-27
CZ288204B6 (en) 2001-05-16
ES2275460T3 (es) 2007-06-16
GR3035601T3 (en) 2001-06-29
HK1005131A1 (en) 1998-12-24
SK281850B6 (sk) 2001-08-06
HUP9601977A3 (en) 1998-04-28
BR9603124A (pt) 1998-04-22
TR199600583A2 (tr) 1997-02-21
JP3891503B2 (ja) 2007-03-14
TW496737B (en) 2002-08-01
DE19526274A1 (de) 1997-01-23
ZA966111B (en) 1997-02-03
SK284733B6 (sk) 2005-10-06
DZ2073A1 (fr) 2002-07-22
CA2181308A1 (fr) 1997-01-20
SV1996000062A (es) 1997-06-26
EP1043332B1 (fr) 2006-11-02
BG62134B1 (bg) 1999-03-31
DE59611398D1 (de) 2006-12-14
NO315926B1 (no) 2003-11-17
HRP960303B1 (en) 2001-08-31
IL118869A0 (en) 1996-10-31
ATE344274T1 (de) 2006-11-15
SA96170491B1 (ar) 2006-09-20
NO963000D0 (no) 1996-07-18
PL315330A1 (en) 1997-01-20
MX9602836A (es) 1997-01-31
PT754678E (pt) 2001-04-30
RU2181123C2 (ru) 2002-04-10
US5935988A (en) 1999-08-10
RO118656B1 (ro) 2003-08-29
SI1043332T1 (sl) 2007-04-30
UA46725C2 (uk) 2002-06-17
EE9600109A (et) 1997-02-17
AU713555B2 (en) 1999-12-02
HU9601977D0 (en) 1996-09-30
DK0754678T3 (da) 2001-02-05
CU22820A3 (es) 2003-01-29
ES2154761T3 (es) 2001-04-16
HUP9601977A2 (en) 1997-05-28
YU20050685A (sh) 2006-08-17
DE59606266D1 (de) 2001-02-08
EE03803B1 (et) 2002-08-15
IL118869A (en) 2002-03-10
SI0754678T1 (en) 2001-04-30
CZ214396A3 (en) 1997-02-12
CO4700525A1 (es) 1998-12-29
JP2007056026A (ja) 2007-03-08
CN1143496A (zh) 1997-02-26
AR003465A1 (es) 1998-08-05
SG47158A1 (en) 1998-03-20
CN1115145C (zh) 2003-07-23
EP0754678B1 (fr) 2001-01-03
MA23940A1 (fr) 1997-04-01
EP0754678A2 (fr) 1997-01-22
AU5948896A (en) 1997-01-23
SK94796A3 (en) 1997-02-05
EP1043332A1 (fr) 2000-10-11
KR970006312A (ko) 1997-02-19
YU41796A (sh) 1999-06-15
DK1043332T3 (da) 2007-03-12
PE9398A1 (es) 1998-04-15
EP0754678A3 (fr) 1997-12-17
KR100433968B1 (ko) 2004-08-30
JPH09202761A (ja) 1997-08-05
PL184861B1 (pl) 2003-01-31
NO963000L (no) 1997-01-20
ATE198469T1 (de) 2001-01-15
NZ299008A (en) 1998-05-27
CZ287896B6 (cs) 2001-03-14

Similar Documents

Publication Publication Date Title
EP0758843A4 (fr) Acides amines modifies en vue de l'administration de medicaments
RU93054168A (ru) Димер молекулярного варианта аро-липопротеина, способ его получения, фармацевтическая композиция на его основе
TNSN95098A1 (fr) Derives de cycloalcanoindoles et de cycloalcanoaza-indoles
ATE211467T1 (de) 4-amino-derivate der mycophenolsäure mit immun suppressiver wirkung
ES2176286T3 (es) Esteres de metido de pentapeptidos inhibidoras del cancer de seres humanos.
ATE210127T1 (de) 6-substituierte mycophenolsäurederivate mit immun suppressiver wirkung
WO1995021919A3 (fr) Proteine a activite de thrombopoietine (tpo)
IL105793A0 (en) Protease and related dna compounds
ES2141164T3 (es) Compuestos amfifilicos derivados de aminoacidos o de peptidos, sus metodos de sintesis y su aplicacion como sistemas de transporte de farmacos.
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
TNSN99133A1 (fr) Procede perfectionne pour la preparation de bases de schiff et produits ainsi obtenus
BR9507858A (pt) Aplicação de um composto inibidor de prolactina para preparar um medicamento para o tratamento de uma disfunção do sistema imunitário aplicação de um composto estimulador de prolactina para preparar um medicamento para o tratamento de uma disfunção do sistema imunitário aplicação de um composto estimulador de prolactina para preparar um medicamento para o tratamento de uma doença autoimunitária e pacote terapêutico
DE69521055D1 (de) Spezifische peptid-wirksamkeit von anti-myelin basischem protein und die anwendung von myelin basischen protein-peptiden an multiple-sklerose-patienten
ES2075465T3 (es) Administracion de compuestos a animales acuaticos realizada mediante ultrasonidos.
NO893882D0 (no) Middel til forbedring av lipidmetabolisme og fremgangsmaate ved anvendelse derav.
WO1996018646A3 (fr) Peptides de proteines de choc thermique et procedes de modulation d'une maladie auto-immune du systeme nerveux central
ZA962715B (en) Pharmaceutical agents for the treatment of Alzheimer's disease.
DE3480764D1 (de) Behandlung von anfaellen und hierfuer nuetzliche pharmazeutische zusammensetzungen.
TR199600583A2 (tr) Farmasötik aktiviteye sahip -amino asitlerin tolere edilebilirliginin arttirilmasi.
ATE214708T1 (de) Kationische mittel zur transfektion von nukleinsäuren
FR2656626B1 (fr) Fragment peptidique comprenant une sequence issue de la proteine 28 kda de schistosoma mansoni et compositions vaccinantes et/ou therapeutiques comprenant ledit fragment.
DE69413637D1 (de) Verwendung von verzweigtkettigen Aminosäuren zur Herstellung eines Arzneimittels zur Behandlung von tardiver Dyskinesia
FR2679235B1 (fr) Methode de purification des aminoacides, des acides nucleiques et de leurs derives.
IL105498A0 (en) Pharmaceutical composition containing ribonucleotide polymerase
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi